You are here

  • Home
  • Archive
  • Volume 88, Issue 5
  • Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

Article metrics

Article menu
Download PDFPDF
Poster Abstracts
Abstracts
62
Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

 

Online download statistics by month:

Online download statistics by month: May 2017 to March 2024

AbstractFullPdf
May 2017131015
Jun 2017148015
Jul 2017162015
Aug 2017250027
Sep 2017314032
Oct 2017506013
Nov 2017698027
Dec 2017520019
Jan 2018492015
Feb 2018337014
Mar 2018517011
Apr 2018422018
May 2018554019
Jun 201842809
Jul 201835205
Aug 201831304
Sep 201839009
Oct 2018292011
Nov 2018386010
Dec 201845208
Jan 2019300013
Feb 2019174011
Mar 201913607
Apr 201913603
May 20198606
Jun 20195004
Jul 201910601
Aug 20196002
Sep 2019108012
Oct 201914205
Nov 20195601
Dec 20197801
Jan 20205803
Feb 20206604
Mar 20205202
Apr 20207200
May 20205600
Jun 20204000
Jul 20204600
Aug 20202600
Sep 20205400
Oct 20207001
Nov 20206001
Dec 20206200
Jan 20212602
Feb 20218603
Mar 202111405
Apr 20214400
May 20212700
Jun 2021105
Jul 2021002
Aug 2021001
Sep 2021004
Oct 202110006
Nov 20215801
Dec 20219402
Jan 20228201
Feb 202213400
Mar 2022166010
Apr 202219003
May 202211407
Jun 20226000
Jul 20223800
Aug 20226400
Sep 20226801
Oct 202216402
Nov 20228000
Dec 20227202
Jan 20234200
Feb 20237601
Mar 20235602
Apr 20235400
May 20233201
Jun 20231800
Jul 20233400
Aug 20232200
Sep 20235400
Oct 20234000
Nov 20237604
Dec 20237000
Jan 20242800
Feb 20244501
Mar 20245601
Total122430440